Scientific Poster Presentation, I

Monday, October 22, 2012: 11:30 AM-1:15 PM
Westin Diplomat Resort
16
Comparison of vitamin D dosing regimens in non-obese and obese patients with low vitamin D levels
Bryan L. Schuessler, Pharm.D., M.S.1, Janelle F. Ruisinger, PharmD2, Dennis W. Grauer, PhD3, Patrick M. Moriarty, MD2 and James M. Backes, PharmD4
1The University of Kansas Hospital, Kansas City, KS
2University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS
3University of Kansas Medical Center, Kansas City, KS
4Mail Stop 4047, University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS
48
Assessment of drug information resource preferences by pharmacy students and faculty
Sabrina W. Cole, PharmD, BCPS and Conor T. Hanrahan, PharmD
Wingate University School of Pharmacy, Wingate, NC
Pharmacokinetics, safety, and antiviral activity of fosamprenavir-containing twice-daily regimens in HIV-infected children 2 to 18 years old: report from APV29005, a 48-week prospective, open-label, multicenter cohort study
Evgeny E. Voronin, M.D., Ph.D.1, Claudia Fortuny, M.D., Ph.D.2, Desamparados Pérez-Tamarit, M.D.3, Dan Duiculescu, M.D., Ph.D.4, Mark F. Cotton, M.D., Ph.D.5, Lisa L. Ross, M.S.6, Susan L. Ford, Pharm.D.6, Yu Lou, M.S.6, Naomi Givens, M.S.7, Katharine Cheng, M.D.7, Jörg Sievers, D.Phil.7 and Gary E. Pakes, Pharm.D.6
1Republic Hospital of Infectious Disease, St. Petersburg, Russia
2Sant Joan de Déu Hospital, Barcelona, Spain
3Hospital Infantil La Fe, Valencia, Spain
4”Dr. Victor Babes” Hospital for Infectious and Tropical Diseases, Bucharest, Romania
5Tygerberg Children's Hospital, Tygerberg, South Africa
6GlaxoSmithKline, Research Triangle Park, NC
7GlaxoSmithKline, Uxbridge, United Kingdom
Steady-state pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir/ritonavir twice-daily regimens in HIV-infected children 4 weeks to <2 years old: results of APV20002, a prospective, open-label, multicenter cohort study
Mark F. Cotton, M.D., Ph.D.1, Haseena Cassim, MBBCh2, Noris Pavía-Ruz, M.D.3, Lisa L. Ross, M.S.4, Susan L. Ford, Pharm.D.4, Yu Lou, M.S.4, Naomi Givens, M.S.5, Katharine Cheng, M.D.5, Jörg Sievers, D.Phil.5 and Gary E. Pakes, Pharm.D.4
1Tygerberg Children's Hospital, Tygerberg, South Africa
2Perinatal HIV Research Unit, Johannesburg, South Africa
3Universidad Nacional Autonoma de Mexico, Facultad de Medicina, Mexico, DF, Mexico
4GlaxoSmithKline, Research Triangle Park, NC
5GlaxoSmithKline, Uxbridge, United Kingdom
Prevalence of HIV-associated neurocognitive disorders (HAND) in virologically suppressed HIV-infected individuals in the ASSURE (EPZ113734) study versus non-HIV-infected control subjects
David A. Wohl, M.D.1, Laveeza Bhatti, M.D., Ph.D.2, Paul Maruff, Ph.D.3, Kevin R. Robertson, Ph.D.4, Catherine B. Small, M.D.5, Howard E. Edelstein, M.D.6, Henry Zhao, Ph.D.7, David A. Margolis, M.D.7, Lisa L. Ross, M.S.7, Mark S. Shaefer, Pharm.D.8 and Gary E. Pakes, Pharm.D.7
1University of NC at Chapel Hill School of Medicine, Division of Infectious Disease, Chapel Hill, NC
2AIDS Healthcare Foundation, Beverly Hills, CA
3CogState Ltd., Melbourne, Australia
4University of NC at Chapel Hill, AIDS Dementia Center, Chapel Hill, NC
5New York Medical College, Valhalla, NY
6Alameda County Medical Center, Oakland, CA
7GlaxoSmithKline, Research Triangle Park, NC
8ViiV Healthcare, Research Triangle Park, NC
HIV-1 drug resistance and mutational profile in fosamprenavir-treated HIV-infected children aged 2 months to 18 years at start of therapy
Lisa L. Ross, MS1, Mark F. Cotton, M.D., Ph.D.2, Haseena Cassim, MBBCh3, Evgeny E. Voronin, M.D., Ph.D.4, Naomi Givens, M.S.5, Jörg Sievers, D.Phil.5, Katharine Cheng, M.D.5 and Gary E. Pakes, Pharm.D.1
1GlaxoSmithKline, Research Triangle Park, NC
2Tygerberg Children's Hospital, Tygerberg, South Africa
3Perinatal HIV Research Unit, Johannesburg, South Africa
4Republic Hospital of Infectious Disease, St. Petersburg, Russia
5GlaxoSmithKline, Uxbridge, United Kingdom
Antiretroviral (ART) therapeutic drug monitoring (TDM) and virologic suppression (VS) in pediatric patients with human immunodeficiency virus
Jomy M. George, PharmD, BCPS1, Tara DeCerbo, PharmD2, Laura L. Bio, Pharm.D., BCPS1, Lori Connelly, RN3 and Laura Pontiggia, PhD4
1Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA
2Thomas Jefferson University Hospital, Philadelphia, PA
3Cooper University Hospital, Camden, NJ
4Misher College of Arts and Sciences, University of the Sciences, Philadelphia, PA
140
Impact of a Pharmacist-conducted Admission Medication Reconciliation Program on Medication Errors
Mitchell S. Buckley, Pharm.D., FCCM, BCPS1, Craig A. Wesley, Pharm.D.1, Butch David, Pharm.D.1, Pamela L. Smithburger, Pharm.D., BCPS2, Sandra Kane-Gill, Pharm.D., MS, FCCM3, Sandeep Devabhakthuni, PharmD, BCPS4, Earnest Alexander Jr., Pharm.D.5 and Lisa M. Harinstein, PharmD6
1Banner Good Samaritan Medical Center, Phoenix, AZ
2University of Pittsburgh Medical Center, Pittsburgh, PA
3University of Pittsburgh School of Pharmacy, Pittsburgh, PA
4University of Maryland School of Pharmacy, Baltimore, MD
5Tampa General Hospital, Tampa, FL
6Cleveland Clinic, Cleveland, OH
141
Assessment of inpatient boxed warning compliance
Megan A. Kloet, PharmD1, Pamela L. Smithburger, Pharm.D., BCPS1, Amy L. Seybert, PharmD, FASHP, FCCP2 and Sandra L. Kane-Gill, PharmD, MSc, FCCM, FCCP2
1University of Pittsburgh Medical Center, Pittsburgh, PA
2University of Pittsburgh School of Pharmacy, Pittsburgh, PA
142
High-risk medications on pharmacy discount program formularies; a brief report
Abir O. Kanaan, PharmD1, Jennifer L. Donovan, PharmD2, Darren M. Triller, PharmD3, Shawn Gagne, BS4 and Jennifer Tjia, MD, MSCE5
1Massachusetts College of Pharmacy and Health Sciences, Worcester, MA
2MCPHS University, Worcester, MA
3IPRO, Albany, NY
4Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA
5Meyers Primary Care Institute, a joint endeavor of the University of Massachusetts Medical School, Reliant Medical Group, and Fallon Community Health Plan, Worcester, MA
143
Does interprofessional medication reconciliation from admission to discharge reduce post-discharge patient emergency department visits and hospital readmissions?
Michelle Baker, BScPhm1, Chaim M. Bell, PhD2, Wei Xiong, MSc1, Edward Etchells, MD, MSc3, Peter Rossos, MD, MBA1, Kaveh Shojania, MD3, Kelly Lane, BSc1, Tim Tripp, BSc, MLIS1, Mary Lam, BSc1, Kimindra Tiwana, BScPhm4, Nita Dhir, MBA1, Derek Leong, BScPhm1, Gary Wong, BScPhm1, Jin Huh, BScPhm1, Emily Musing, MHSc1 and Olavo Fernandes, Pharm.D1
1University Health Network, Toronto, ON, Canada
2St. Michael's Hospital, Toronto, ON, Canada
3Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4Institute for Safe Medication Practices Canada, Toronto, ON, Canada
Effects of the ESRD medicare bundling rule on anemia management in private dialysis units
Natsuki Kubotera, BS, Amy Barton Pai, BS, Pharm.D., BCPS and Katie Cardone, Pharm.D.
Albany College of Pharmacy and Health Sciences, Albany, NY
145
Incidence and Predictors of Hepatitis B Vaccine Non-Response among Hemodialysis Patients
Magdalene M. Assimon, Pharm.D., M.S.1, Emily Bruni, Pharm.D., Student1, Louise-Ann McNutt, Ph.D.2, Darius L. Mason, Pharm.D., BCPS1 and Nimish Patel, Pharm.D., M.S., AAHIVP1
1Albany College of Pharmacy & Health Sciences, Albany, NY
2University at Albany, School of Public Health, Rensselaer, NY
146
Comparison of the Chronic Kidney Disease Epidemiology Collaboration, Modification of Diet in Renal Disease, and Cockcroft-Gault Equations for Drug Dosing in the Elderly Population
M. Shawn McFarland, Pharm.D.1, Christina F. Burger, Pharm.D.1, Alex K. Stephens, Pharm.D.1, Joanna Q. Hudson, PharmD2 and Jennifer R. Bean, Pharm.D.1
1VA Tennessee Valley Healthcare System, Murfreesboro, TN
2University of Tennessee, Memphis, TN
159
Reduction in toll-like receptor-4 (tlr-4) on blood mononuclear cells after 3 weeks of rosuvastatin treatment in healthy male subjects
Timothy R. McGuire, Pharm.D., FCCP, BCOP1, Paul P. Dobesh, Pharm.D., FCCP, BCPS1, Donald G. Klepser, Ph.D.1, Andre C. Kalil, MD2 and Keith Olsen, Pharm., D., FCCP1
1University of Nebraska Medical Center, Omaha, NE
2Internal Medicine, University of Nebraska Medical Center, Omaha, NE
160
Evaluation of Jamaican Knowledge of Diabetes and Health Beliefs
Melody L. Hartzler, PharmD, AE-C1, Aleda M. H. Chen, PharmD, PhD1, Bethany L. Murphy, PharmD2 and Sarah J. Rodewald, BSN3
1Cedarville University School of Pharmacy, Cedarville, OH
2Union University School of Pharmacy, Jackson, TN
3Miami Valley Hospital, Dayton, OH
161
ACCP Ambulatory Care Practice and Research Network (PRN): recent PRN activities and assessment of membership diversity over the last decade
Lea E. dela Pena, PharmD, BCPS1, Kassandra Bartelme, Pharm.D., BCACP2, Catherine A. Bourg, Pharm.D., BCPS, BCACP3, Jennifer D'Souza, PharmD, CDE, BC-ADM4, Katherine R. Gerrald, PharmD, BCPS, BCACP5, Brian K. Irons, Pharm.D., FCCP, BCACP, BCPS, BC-ADM6, Emily K. McCoy, PharmD, BCACP7, Daniel M. Riche, Pharm.D., BCPS, CDE8 and Nicole Rockey, PharmD, BCACP1
1Midwestern University Chicago College of Pharmacy, Downers Grove, IL
2Concordia University Wisconsin School of Pharmacy, Mequon, WI
3University of Georgia College of Pharmacy, Athens, GA
4Dreyer Medical Clinic & Midwestern University Chicago College of Pharmacy, Downers Grove, IL
5Presbyterian College School of Pharmacy, Clinton, SC
6TTUHSC School of Pharmacy, Lubbock, TX
7Auburn University, Harrison School of Pharmacy, Birmingham, AL
8University of Mississippi School of Pharmacy, Jackson, MS
162
Integrating clinical pharmacists and industrial engineers' perspectives to develop a codebook to characterize structure at anticoagulation clinics
Abir O. Kanaan, PharmD1, Jennifer L. Donovan, PharmD2, Mustafa Ozkaynak, PhD3, Sharon Johnson, PhD3, Bengisu Tulu, PhD3 and Adam Rose, MD4
1Massachusetts College of Pharmacy and Health Sciences, Worcester, MA
2MCPHS University, Worcester, MA
3WPI, Worcester, MA
4Bedford VA Medical Center, Bedford, MA
163
Patient satisfaction with an inpatient pharmacist-directed anticoagulation service
Charles T. Makowski, Pharm.D.1, Carrie W. Nemerovski, PharmD, BCPS, (AQ-CV)2, Douglas L. Jennings, PharmD, BCPS, (AQ-CV)2 and James S. Kalus, PharmD, BCPS, (AQ-CV)2
1Wayne State University Eugene Applebaum College of Pharmacy, Detroit, MI
2Henry Ford Hospital, Detroit, MI
164
Opioid Utilization Patterns among Cancer Patients: An Analysis Using the Chronic Opioid Medication Use Evaluation (MUE) Tool
Anisha M. Patel, MS, Jacqueline A. Pesa, PhD, MPH, Andrew Howe, PharmD and Samir H. Mody, PharmD, MBA
Janssen Scientific Affairs, LLC, Raritan, NJ
165
Assessment of Impact of a Pharmacist-Run Pain Clinic on Patient Outcomes in Hypertension, Diabetes, and Hyperlipidemia
Melissa R. Mahoney, BS, PharmD and Jennifer Patton, PharmD
Memphis VA Medical Center, Memphis, TN
227
Multiple regression analysis of factors predicting mycophenolic acid free fraction in 91 adult organ transplant recipients
Tony KL Kiang, BSc(Pharm), PhD, ACPR1, Karen OY Ng, BSc(Pharm), ACPR2 and Mary HH Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS3
1Department of Pharmacy, Vancouver General Hospital, Vancouver, BC, Canada
2Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada
3The University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada
See more of: Original Research